Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Real Life Experience

泊马度胺 医学 来那度胺 耐受性 内科学 不良事件通用术语标准 地塞米松 多发性骨髓瘤 不利影响 肿瘤科 血液学 外科
作者
Chiara Cantò,Elena Ranucci,Stefano Pulini,Fiorenzo Santoleri,Anna Morelli,Francesca Fioritoni,Simona Falorio,Lorenza Torti,Antonio Spadano,Marianna D'Aloisio,Mauro Di Ianni,Stella Santarone,Paolo Di Bartolomeo
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 5653-5653
标识
DOI:10.1182/blood-2018-99-112595
摘要

Abstract Introduction Multiple Myeloma (MM) is a hematologic malignancy characterized by proliferation of clonal plasmacells in the bone marrow and sometimes extramedullary sites which inevitably tend to relapse. Patients with relapsed/refractory MM (R/R MM) who are treated with conventional drugs as immunomodulating agents (IMiDs) and proteasoma inhibitors (PIs) have a poor survival. Based on the results of MM 003 phase III randomised trial, pomalidomide in association with dexamethasone has shown to improve R/R MM outcome. We conducted a single-center real life-based observational and pharmacological analysis to investigate the efficacy and tolerability of pomalidomide in a group of patients with R/R MM previously exposed to IMiDs and PIs. Method and Materials We included 34 patients (females 21) treated with pomalidomide (POMA) from January 2015 to May 2018 at the Hematology Department of "Santo Spirito" Hospital in Pescara, Italy. All patients were diagnosed by R/R MM according to IMWG guidelines and were classificated using ISS criteria. Prognostic cytogenetic value was identified by FISH analysis. POMA was administred at the oral daily dose of 3-4 mg (days 1-21) in combination with oral dexamethasone (days 1,8,15,22) at the dosage of 20 mg/day. Adverse events were evaluated according to the common terminology criteria for adverse reactions (CTCAE version 4.0). Overall survival (OS) and progression free survival (PFS) were designed according to Kaplan-Myer method. The adherence to therapy was determined using 'received daily dose/prescribed daily dose' method (RDD/PDD). Statistic analysis were conducted with GraphPad Prism 7.0; p values ≤ 0.05 were considered statistically significant. Results The clinical and biological characteristics of 34 patients are described in Tab.1. The median follow up after POMA therapy was 5 months (range, 1-32); at the end of this period 12 patients had completed at least 6 cycles of therapy (range, 1-21). Overall response rate (ORR) was 24%: 4 complete remission (CR), 3 very good partial response (VGPR), 1 partial response (PR); moreover 6 patients (18%) achieved a minimal response (MR). Clinical benefit rate (CBR) was 74%: ORR plus 6 MR and 11 stable disease (SD). At time of this report 12 patients (35%) are living. Among living patients, 4 are now receiving other treatments and 8 are still under POMA treatment: 4 are in CR, 1 is in PR, 1 in MR and 2 in SD. Median OS of all patients was 10 months, whereas median PFS was 6 months (Fig.1,A-B). Median PFS was notably lower in high cytogenetic risk patients (4 months) as compared to the PFS of standard cytogenetic risk patients (16 months) (p= 0.02) (Fig.1,D). Patients treated with at least 4 previous lines of therapy had a median PFS of 5 months, while those receiving until 3 previous lines of therapy had a median PFS of 24 months (p= 0.01) (Fig.1,C). Patients receiving a drug regimen lenalidomide-based as last treatment before starting POMA didn't show significant difference in PFS from those receiving other treatments (4 months vs 6 months) (p=NS). During treatment with POMA, 22 patients (65%) showed adverse drug reactions (ADRs) for a total of 77. Seventy-four ADRs were ≥ 2 grade. Forty nine ADRs (63%) were hematological and 43 ADRs (56%) occurred in the first 3 months of therapy. In particular Twenty-two of them occurred within the first month of therapy. Thirty two cases of ADRs (41%) were successfully managed with simple delay of treatment. As consequence, the adherence to therapy was not optimal (78%). However only 9 (12%) of the total ADRs were cause of end of treatment. Conclusions Despite the low sample size and short follow-up, our real life analysis contributes to show that pomalidomide therapy is a favorable option for patients with R/R MM, leading to good responses in terms of OS and PFS. The best results were obtained when POMA treatment was utilized at first relapses and in particular in patients with favorable genetic profile. About the safety, despite the frequent hematological toxicity, ADRs can be quite easily managed to allow few interruptions of the treatment and improve the adherence. Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
渣渣XM发布了新的文献求助100
刚刚
李离子完成签到,获得积分10
刚刚
Lee完成签到,获得积分10
刚刚
1秒前
地黄饮子的应助被zhang采纳,获得10
1秒前
完美世界的应助被baobao采纳,获得10
1秒前
鹿过完成签到,获得积分10
2秒前
Jasper的应助被调皮钧采纳,获得10
2秒前
侯小遥发布了新的文献求助10
2秒前
hua发布了新的文献求助10
2秒前
凯哥完成签到 ,获得积分10
2秒前
wanci的应助被leotao采纳,获得10
3秒前
jack发布了新的文献求助10
3秒前
Sunjz完成签到,获得积分10
3秒前
脑洞疼的应助被小海螺采纳,获得10
3秒前
wangzong发布了新的文献求助30
4秒前
zhou完成签到,获得积分10
4秒前
宁语完成签到,获得积分10
4秒前
liuchair完成签到,获得积分10
4秒前
李离子发布了新的文献求助10
4秒前
Koi完成签到,获得积分10
5秒前
5秒前
5秒前
糊涂的踏歌完成签到,获得积分10
5秒前
东风完成签到,获得积分10
5秒前
6秒前
沉静土豆发布了新的文献求助10
6秒前
彭于晏的应助被阳光的荠采纳,获得10
6秒前
7秒前
7秒前
今天不下雨完成签到,获得积分10
7秒前
努力努力再努力完成签到,获得积分10
8秒前
友好的芷雪完成签到,获得积分10
8秒前
高志远发布了新的文献求助10
8秒前
汉堡包的应助被酷酷柚子采纳,获得10
8秒前
8秒前
9秒前
邓巧发布了新的文献求助10
9秒前
ding的应助被李离子采纳,获得10
10秒前
wjw完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181014
求助须知:如何正确求助?哪些是违规求助? 9571039
关于积分的说明 21816042
捐赠科研通 7777369
什么是DOI,文献DOI怎么找? 3433378
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479385